The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
Travel, Accommodations, Expenses - Pfizer; Pfizer (I)
Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.
 
Dawei Xuan
No Relationships to Disclose
 
Xiaohua (Robert) Xin
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Brenda Gibson
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Tenshang Joh
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Hequn Yin
Employment - Novartis; Pfizer
Stock and Other Ownership Interests - Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Pamela D. Garzone
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Jasgit C. Sachdev
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene
 
Michael L. Maitland
Consulting or Advisory Role - Bayer (I); Gilead Sciences (I); Merck Sharp & Dohme (I); United Therapeutics (I)
 
Manish Sharma
Consulting or Advisory Role - Abbvie; Bayer; Eisai; Ipsen; Taiho Pharmaceutical
 
Victor Moreno
No Relationships to Disclose
 
Emiliano Calvo
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Celgene; Cerulean Pharma; EUSA Pharma; Janssen-Cilag; Nanobiotix; Novartis; Pierre Fabre; PsiOxus Therapeutics; Seagen
Speakers' Bureau - Novartis
Research Funding - Abbvie; Amcure; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; H3 Biomedicine; Incyte; Janssen Oncology; Kura Oncology; Lilly; Loxo; Macrogenics; Menarini; Merck; Merck Serono; Merus; Millennium; Nanobiotix; Nektar; Novartis; Pfizer; PharmaMar; Principa Biopharma; PsiOxus Therapeutics; Puma Biotechnology; RigonTEC; Roche/Genentech; Sanofi; Synthon; Taiho Pharmaceutical; Tesaro
Travel, Accommodations, Expenses - Celgene; Novartis
 
Shivaani Kummar
Consulting or Advisory Role - Corvus Pharmaceuticals; MedTree (I); Nodus Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Pfizer (Inst); Plexxikon (Inst)
 
Erica Michelle Stringer-Reasor
Honoraria - Breast Cancer Index; Lilly
Research Funding - Corcept Therapeutics (Inst)
Travel, Accommodations, Expenses - Cascadian Therapeutics
 
Nehal J. Lakhani
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Amgen (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Forty Seven (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Anthony W. Tolcher
Employment - New Experimental; START
Leadership - Symphony Evolution
Consulting or Advisory Role - AbbVie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Elekta (Inst); EMD Serono (Inst); Formation Biologics (Inst); Genmab (Inst); Idea Pharma (Inst); Ignyta (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Alexion Pharmaceuticals (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst)
 
Darrin M. Beaupre
Employment - Pfizer; Pharmacyclics
Leadership - Pfizer; Pharmacyclics
Stock and Other Ownership Interests - Pfizer; Pharmacyclics
Patents, Royalties, Other Intellectual Property - Pharmacyclics
Travel, Accommodations, Expenses - Pfizer; Pharmacyclics